ABSTRACT
Objective:Through analyzing pulmonary function and clinical characteristics of preterm infants with bronchopulmonary dysplasia (BPD) from 0 to 6 months, the characteristics of pulmonary function in infants with BPD were investigated.Methods:A retrospective study was conducted on 85 infants hospitalized in the Department of Neonatology of the First Affiliated Hospital of Shantou University Medical College from December 2015 to December 2017, including 25 preterm infants with BPD (BPD group), 30 preterm infants without BPD (preterm control group), and 30 term infants without respiratory diseases (full-term control group), respectively.Pulmonary function were tested in preterm infants at 37 to 41 weeks of corrected age as well as at 6 months of corrected age, and full-term infants at 3 days to 1 week after birth as well as at 6 months old.The outcomes of respiratory system diseases at 6 months of corrected age in two groups of preterm infants were followed up.Results:(1) While preterm infants at 37 to 41 weeks of corrected age and full-term infants at 3 days to 1 week after birth, time to peak tidal expiratory flow/expiratory time(TPTEF/TE)and volume to peak tidal expiratory flow/exhaled volume(VPTEF/VE) of BPD group were lower than those of the other two groups ( P<0.05), while the differences between preterm control group and full-term control group is not significant.VPTEF, peak expiratory flow (PEF), tidal expiratory flow when 75% of tidal volume reminds in the lung (TEF75%), TEF50%, TEF25% in BPD group and preterm control group were lower than those in the full-term group ( P<0.05). The differences between BPD group and preterm control group were not significant ( P>0.05). The BPD group had significantly lower TPTEF/TE, VPTEF/VE and ratio of tidal expiratory flow and tidal inspiratory flow when 50% of tidal volume reminds in the lung (TEF50%/TIF50%) and higher VPTEF, PEF, TEF25% at 6 months of corrected age than those at 37 to 41 weeks of corrected age ( P<0.05). While at 6 months of corrected age, the BPD group had higher PEF than that in the preterm control group ( P<0.05). There was no statistically significant difference between that in the occurrence of lower respiratory tract infections (43.3% vs.16.7%), wheezing (21.7% vs.8.3%), rehospitalization (39.1% vs.16.7%) between BPD group and preterm control group within 6 months of corrected age ( P>0.05). Conclusion:Infants with BPD had small airway obstruction at 37 to 41 weeks of corrected age and may not improve significantly at 6 months of corrected age.
ABSTRACT
Decision-making aid for cancer patients is of great significance in the diagnosis and treatment for diseases. Breast cancer is one of the most common malignant tumors in women all over the world, and breast cancer patients have become the main target population for decision-aided research. Application of decision-making assistance for patients in Western countries has developed to a certain extent, while relevant research in China is still at the early stage. There are kinds of intervention forms for patients' decision aids, including traditional brochures and videos, decision aids systems, decision coaching, multidisciplinary breast cancer teams, etc. The tools for decision-making quality evaluation include the patients' awareness for decision-making, participation, decision-making conflict, decision-making satisfaction, decision-making regret, which can provide important guidance for the application of decision-making aid treatment in breast cancer patients in the future.
Subject(s)
Female , Humans , Breast Neoplasms/therapy , China , Decision Making , Emotions , Personal SatisfactionABSTRACT
In recent years, with the high incidence of lung cancer and mortality, the disease-relevant mental health problems such as depression began to attract attention. A growing number of studies have also begun to hypothesize and confirm the relationship between depression and survival or mortality in patients with lung cancer, and have made some progress in basic research, prospective cohort research and intervention research. In basic research, cancer can cause depression due to mediating the production of inflammatory factors, and the genotype of tumor epidermis growth factor receptor (EGFR) can explain the high mortality and risk of depression in patients with lung cancer from a certain point of view. Different studies in prospective cohort studies argue that depression is an important predictor of survival in patients with lung cancer and need to be further studied. In the aspect of intervention research, although some studies have confirmed the potential of antidepressants in anti-tumor oxidative therapy, there is no enough evidence in psychological intervention and drug intervention to prove their effectiveness in improving the survival outcome of lung cancer. In the future, it is necessary to further explore the possible mechanisms for antidepressants and psychological intervention to improve the survival time of the patients.